Recent Quotes (30 days)

You have no recent quotes
chg | %

TBG Diagnostics Ltd  

(Public, ASX:TDL)   Watch this stock  
Find more results for ASX: TBG
0.0830
0.0000 (0.00%)
Oct 16 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range     -
52 week 0.04 - 0.24
Open     -
Vol / Avg. 0.00/2,902.00
Mkt cap 18.06M
P/E     -
Div/yield     -
EPS -0.02
Shares 217.59M
Beta     -
Inst. own     -
Nov 24, 2017
TBG Diagnostics Ltd Annual Shareholders Meeting (Estimated) - 11:00AM GMT+11 - Add to calendar
Aug 30, 2017
Preliminary 2017 TBG Diagnostics Ltd Earnings Release (Estimated)
Aug 28, 2017
Interim 2017 TBG Diagnostics Ltd Earnings Release
  

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -56.52% -
Operating margin -56.52% -
EBITD margin - -
Return on average assets -9.29% -
Return on average equity -9.72% -
Employees 41 -
CDP Score - -

Address

2806 Ipswich Rd
BRISBANE, QLD 4076
Australia
+61-7-30887926 (Phone)
+61-7-33944394 (Fax)

Website links

Description

TBG Diagnostics Limited, formerly Progen Pharmaceuticals Limited, is a biotechnology company. The Company's principal activities include the discovery, research and development of pharmaceutical therapeutics for the treatment of human diseases, and the provision of contract services related to the process development, manufacture and quality assurance of biopharmaceutical products. The Company's segments include Research & Development, and Manufacturing. The Company is primarily engaged in the discovery and development of small molecule-based cancer therapeutics. The Company is focused on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The Company's offerings include Muparfostat (PI-88) and PG545. Muparfostat (PI-88) is an anti-angiogenesis and anti-metastatic compound. Muparfostat (PI-88) is a dual angiogenesis and heparanase inhibitor. PG545 is an agent designed to target the tumor microenvironment.

Officers and directors

Indrajit Solomon Arulampalam Executive Chairman of the Board
Leslie Tillack Chief Executive Officer - Pharmasynth
Lee Horobin CPA General Manager - Finance
Yu-Zen Cheng Executive Director
Keith Dredge Director of Drug Development
Fleur Lankesheer Director - Business Development and Legal
Justyn Stedwell Company Secretary
Chia-Chuan Chang Non-Executive Director
Shi-Chung Chang M.D. Non-Executive Director
Emily Lee Non-Executive Director